Orasure Technologies Inc. OSUR

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001116463

C

middle fifth of 369 graded peers in healthcare

rank 171 of 369; percentile 46.2; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise




Scoreboard	
Profitability	D percentile 67.4
Solvency	A/B percentile 21.5
Growth and financing	C percentile 51.1
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $403.2M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 9, 2026 249 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$3.62 2026-11-12; market equity $250.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. In November 2025, the Company acquired BioMedomics, Inc. ("BioMedomics"). BioMedomics' SickleSCAN® test is the world's first rapid point-of-care test for sickle cell disease.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 67.4						
Gross profitability	12.0%	32.3%		73.9	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(4.5%)	(6.6%)	63.6	800	2025-12-31
Gross margin stability, five years	3.9 pts	2.8 pts	64.7	242	2025-12-31
Solvency, sleeve percentile 21.5					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	6.76	(0.35)	14.9	744	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2012-12-31; latest annual assets end 2025-12-31					
Current ratio	6.58x	2.95x	28.1	826	2025-12-31
Growth and financing, sleeve percentile 51.1					
Revenue growth, three-year compound	(33.3%)	10.1%	92.7	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(3.2%)	2.2%	59.2	694	2025-12-31
Net share issuance, one year	(7.6%)	2.5%	1.4	627	2026-02-28

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
166	Innoviva, Inc. (INVA)	44.8	C	
167	Integer Holdings Corp. (ITGR)	45.1	C	
168	Pediatrix Medical Group, Inc. (MD)	45.4	C	
169	Zimmer Biomet Holdings, Inc. (ZBH)	45.7	C	
170	Anika Therapeutics, Inc. (ANIK)	45.9	C	fortress balance sheet
171	Orasure Technologies Inc. (OSUR)	46.2	C	
172	Johnson & Johnson (JNJ)	46.5	C	
173	Enovis Corp. (ENOV)	46.7	C	
174	Align Technology Inc. (ALGN)	47.0	C	
175	ImmunityBio, Inc. (IBRX)	47.3	C	short runway, distress
176	Kymera Therapeutics, Inc. (KYMR)	47.6	C	dilution

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	43.1%	(1.9%)	75
Distance from 52-week high	(19.6%)	(30.8%)	61
EBIT to enterprise value	not computable	(1.9%)	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	(21.3%)	(1.0%)	24
Book value to price	1.23	0.28	90
Sales to price	0.46	0.29	62
Composite equity issuance, five years	(4.1%)	20.5%	22
Relative strength against the sector, log excess return	0.19	(0.19)	75

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$148.2M
Operating cash flow, four quarters	-$43.7M
Months of runway	40.7
Days since last periodic filing	4 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$1.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$48.2M	2025-12-31	2026-03-09	10-K	26-000016
2	assets	us-gaap:Assets	$403.2M	2025-12-31	2026-03-09	10-K	26-000016
3	net income	us-gaap:NetIncomeLoss	-$68.7M	2025-12-31	2026-03-09	10-K	26-000016
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$49.0M	2025-12-31	2026-03-09	10-K	26-000016
5	assets	us-gaap:Assets	$479.7M	2024-12-31	2026-03-09	10-K	26-000016
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$115.0M	2025-12-31	2026-03-09	10-K	26-000016
7	gross profit	us-gaap:GrossProfit	$79.4M	2024-12-31	2026-03-09	10-K	26-000016
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$185.8M	2024-12-31	2026-03-09	10-K	26-000016
9	gross profit	us-gaap:GrossProfit	$171.7M	2023-12-31	2026-03-09	10-K	26-000016
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$405.5M	2023-12-31	2026-03-09	10-K	26-000016
11	gross profit	us-gaap:GrossProfit	$148.4M	2022-12-31	2025-03-07	10-K	25-000010
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$387.5M	2022-12-31	2025-03-07	10-K	25-000010
13	gross profit	us-gaap:GrossProfit	$117.6M	2021-12-31	2024-03-11	10-K	24-000012
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$233.7M	2021-12-31	2024-03-11	10-K	24-000012
15	current assets	us-gaap:AssetsCurrent	$261.9M	2025-12-31	2026-03-09	10-K	26-000016
16	current liabilities	us-gaap:LiabilitiesCurrent	$39.8M	2025-12-31	2026-03-09	10-K	26-000016
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$172.2M	2025-12-31	2026-03-09	10-K	26-000016
18	operating income	us-gaap:OperatingIncomeLoss	-$72.0M	2025-12-31	2026-03-09	10-K	26-000016
19	book equity	us-gaap:StockholdersEquity	$340.8M	2025-12-31	2026-03-09	10-K	26-000016
20	liabilities	us-gaap:Liabilities	$62.3M	2025-12-31	2026-03-09	10-K	26-000016
21	operating income	us-gaap:OperatingIncomeLoss	-$16.3M	2012-12-31	2015-03-12	10-K	15-089338
22	interest expense	us-gaap:InterestExpense	$172,000	2012-12-31	2015-03-12	10-K	15-089338
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.2M	2025-12-31	2026-03-09	10-K	26-000016
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$27.4M	2024-12-31	2026-03-09	10-K	26-000016
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.8M	2024-12-31	2026-03-09	10-K	26-000016

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$141.6M	2023-12-31	2026-03-09	10-K	26-000016
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.8M	2023-12-31	2026-03-09	10-K	26-000016
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$47.2M	2022-12-31	2025-03-07	10-K	25-000010
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.8M	2022-12-31	2025-03-07	10-K	25-000010
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$10.2M	2025-12-31	2026-03-09	10-K	26-000016
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$64.6M	2025-12-31	2026-03-09	10-K	26-000016
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.8M	2025-12-31	2026-03-09	10-K	26-000016
33	current assets	us-gaap:AssetsCurrent	$333.2M	2024-12-31	2026-03-09	10-K	26-000016
34	current liabilities	us-gaap:LiabilitiesCurrent	$33.5M	2024-12-31	2026-03-09	10-K	26-000016
35	assets	us-gaap:Assets	$482.8M	2023-12-31	2025-03-07	10-K	25-000010
36	assets	us-gaap:Assets	$444.2M	2022-12-31	2024-03-11	10-K	24-000012
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	69,126,173	2026-02-28	2026-03-09	10-K	26-000016
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	74,800,131	2025-02-24	2025-03-07	10-K	25-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.